Understanding Mann Says Fda Audit Delayed Decision On Inhaled Insulin
Exploring Mann Says Fda Audit Delayed Decision On Inhaled Insulin reveals several interesting facts. Jan. 10 (Bloomberg) -- Alfred
Key Takeaways about Mann Says Fda Audit Delayed Decision On Inhaled Insulin
- MannKind Corp Call |
- "MannKind (MNKD) is down after it said it is eliminating 41 percent of its staff, 179 employees, following notification from the U.S. ...
- In a comparison of premeal inhaled Technosphere insulin plus glargine with twice-daily 70/30 insulin, the
- MannKind Corporation (NASDAQ:MNKD) reported a Q1 loss of $0.34 yesterday afternoon, a wider loss than the consensus ...
- No needles, no pricks, and no pumps. If you're a diabetic, your next dose of
Detailed Analysis of Mann Says Fda Audit Delayed Decision On Inhaled Insulin
Dec. 28 (Bloomberg) -- MannKind Corp., the biotechnology company founded by the billionaire inventor Alfred MannKind Corp. (MNKD) is under early selling pressure and down 2.79% in morning trading, after the company said it will have to ... MannKind (MNKD) announced that it was informed on December 27 by the U.S. Food & Drug Administration (
FDA approval of Afrezza makes evening news
Stay tuned for more updates related to Mann Says Fda Audit Delayed Decision On Inhaled Insulin.